Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma (Journal article)

Karavasilis, V./ Malamou-Mitsi, V./ Briasoulis, E./ Tsanou, E./ Kitsou, E./ Pavlidis, N.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorTsanou, E.en
dc.contributor.authorKitsou, E.en
dc.contributor.authorPavlidis, N.en
dc.rightsDefault Licence-
dc.subjectAntigens, CD34/analysis/*biosynthesisen
dc.subjectAntineoplastic Agents/therapeutic useen
dc.subjectGynecologic Surgical Proceduresen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectNeovascularization, Pathologic/*physiopathologyen
dc.subjectOvarian Neoplasms/chemistry/*metabolism/*pathology/therapyen
dc.subjectPlatinum Compounds/therapeutic useen
dc.subjectThrombospondin 1/analysis/*biosynthesisen
dc.subjectVascular Endothelial Growth Factor A/analysis/*biosynthesisen
dc.titleClinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinomaen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractThe aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery and received platinum-based chemotherapy. The tissue expression of CD34, vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1) was assessed immunohistochemically. CD34 stained hot spot areas were used to evaluate tumor microvessel density (MVD). VEGF and TSP-1 were assessed by semiquantitative methods. The studied molecules were investigated for relationship with standard clinicopathologic parameters. MVD count was high: median value of 39, range 12-143 microvessels/mm2. VEGF was present in all cases and stained strong in 91%. Stroma staining for TSP-1 was weak in 79% of the cases, strong in 6%, and absent in five (15%). We did not find correlations between the three studied markers and histologic type or tumor grade. MVD score did not relate to VEGF or TSP-1. We only observed a trend toward a longer survival in patients with tumors expressing high TSP-1 (60 vs. 36 months, P= 0.1). Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas. The findings of this study may offer support for considering VEGF-targeted therapeutics in ovarian cancer treatment research.en
heal.journalNameInt J Gynecol Canceren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.